USANA Health Sciences financials
$14.70−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jan 3 | FY24 Dec 28 | FY23 Dec 30 | FY22 Dec 31 | FY21 Jan 1 | FY20 Jan 2 | FY19 Dec 28 | FY18 Dec 29 | FY17 Dec 30 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B |
| Gross profit | $724.4M | $693.3M | $744.3M | $804.7M | $968.6M | $925.5M | $873.4M | $988.5M | $867.9M | $825.9M |
| Gross margin | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% | 81.6% | 82.3% | 83.1% | 82.9% | 82.1% |
| Operating income | $37.4M | $66.3M | $93.1M | $107.6M | $170.2M | $176.5M | $146.2M | $188.4M | $132.5M | $138.6M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M | $116.5M | $124.7M | $100.5M | $126.2M | $62.5M | $100.0M |
| Net margin | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% |
| Diluted EPS | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 |
| EBITDA | $83.4M | $80.9M | $105.8M | $121.0M | $192.4M | $199.0M | $169.2M | $205.2M | $148.6M | $152.1M |
| Operating cash flow | $22.3M | $61.0M | $70.6M | $103.9M | $121.2M | $160.7M | $127.0M | $157.0M | $124.1M | $137.7M |
| Free cash flow | $8.5M | $50.9M | $56.1M | $93.5M | $108.5M | $145.6M | $110.4M | $145.5M | $110.8M | $105.0M |
| Diluted shares | 18.6M | 19.2M | 19.3M | 19.3M | 20.3M | 21.3M | 22.8M | 24.6M | 24.7M | 25.0M |
Balance sheet
| Period end | Jan 3 | Dec 28 | Dec 30 | Dec 31 | Jan 1 | Jan 2 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $158.4M | $181.8M | $330.4M | $288.4M | $239.8M | $311.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $14.0M | $23.0M | $786.0K | $0.00 | $0.00 | $0.00 |
| Total assets | $742.9M | $748.2M | $632.8M | $596.5M | $577.7M | $640.9M |
| Total liabilities | $156.6M | $161.9M | $135.6M | $162.1M | $182.6M | $199.2M |
| Shareholders' equity | $586.3M | $532.1M | $497.2M | $434.5M | $395.1M | $441.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology